A Study Investigating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs NNC 0363 1063 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novo Nordisk
- 19 Nov 2024 Status changed from not yet recruiting to recruiting.
- 19 Nov 2024 New trial record